AC Immune SA

How big is AC Immune SA?

As of Jun 18, AC Immune SA has a market capitalization of 201.92 million and reported net sales of 32.57 million with a net profit of -57.98 million over the latest four quarters. Shareholder's funds are 123.88 million, and total assets amount to 254.80 million.

As of Jun 18, AC Immune SA has a market capitalization of 201.92 million, categorizing it as a Micro Cap company.<BR><BR>As of Jun 18, the sum of net sales for the latest four quarters is 32.57 million, while the sum of net profit for the same period is -57.98 million.<BR><BR>As of Dec 24, the shareholder's funds are reported at 123.88 million, and total assets amount to 254.80 million.

What does AC Immune SA do?

AC Immune SA is a Switzerland-based biopharmaceutical company focused on precision medicine for neurodegenerative diseases. As of March 2025, it reported net sales of $1 million and a net loss of $21 million, with a market cap of $201.92 million.

Overview:<BR>AC Immune SA is a Switzerland-based clinical-stage biopharmaceutical company focused on precision medicine for neurodegenerative diseases within the Pharmaceuticals & Biotechnology industry.<BR><BR>Financial Snapshot:<BR>- Most recent Net Sales: 1 Million (Quarterly Results - Mar 2025)<BR>- Most recent Net Profit: -21 Million (Quarterly Results - Mar 2025)<BR>- Market cap: USD 201.92 Million (Micro Cap)<BR><BR>Key Metrics:<BR>- P/E: NA (Loss Making)<BR>- Industry P/E: NA<BR>- Dividend Yield: 0.00%<BR>- Debt Equity: -1.53<BR>- Return on Equity: -54.12%<BR>- Price to Book: 1.88<BR><BR>Contact Details:<BR>- Address: EPFL Innovation Park, Building B, LAUSANNE None: 1015<BR>- Tel: ['41 21 3459121', '41 21 3459121']<BR>- Fax: 41 21 3459120<BR>- Website: https://www.acimmune.com/

Who are in the management team of AC Immune SA?

As of March 2022, the management team of AC Immune SA includes Dr. Douglas Williams (Non-Executive Independent Chairman), Prof. Dr. Andrea Pfeifer (CEO and Co-Founder), Mr. Martin Velasco (Non-Executive Independent Vice Chairman), and several Non-Executive Independent Directors: Dr. Peter Bollmann, Mr. Thomas Graney, and Dr. Werner Lanthaler. This team oversees the company's strategic direction and governance.

As of March 2022, the management team of AC Immune SA includes the following individuals:<BR><BR>- Dr. Douglas Williams, who serves as the Non-Executive Independent Chairman of the Board.<BR>- Prof. Dr. Andrea Pfeifer, who is the Chief Executive Officer, Co-Founder, and Director.<BR>- Mr. Martin Velasco, who holds the position of Non-Executive Independent Vice Chairman of the Board.<BR>- Dr. Peter Bollmann, who is a Non-Executive Independent Director.<BR>- Mr. Thomas Graney, also a Non-Executive Independent Director.<BR>- Dr. Werner Lanthaler, who serves as a Non-Executive Independent Director. <BR><BR>This team is responsible for guiding the company's strategic direction and governance.

Should I buy, sell or hold AC Immune SA?

Is AC Immune SA overvalued or undervalued?

As of March 14, 2024, AC Immune SA is considered risky and overvalued due to negative earnings and significant losses, reflected in its financial ratios, and has underperformed the market with a return of -30.58% over the past year.

As of 14 March 2024, the valuation grade for AC Immune SA has moved from does not qualify to risky, indicating a shift in perception towards the company's financial health. The company appears to be overvalued, given its negative earnings and significant losses reflected in key ratios. The price-to-book value stands at 2.00, while the EV to EBITDA and EV to EBIT ratios are both negative at -0.93 and -0.89, respectively, highlighting the challenges in generating positive cash flows.<BR><BR>In comparison with peers, AC Immune SA's P/E ratio is not applicable due to its loss-making status, while Lexicon Pharmaceuticals has a P/E of -3.53 and Vanda Pharmaceuticals has a P/E of -4.02, indicating that AC Immune is not alone in facing valuation challenges within this sector. Over the past year, AC Immune SA has underperformed significantly, with a return of -30.58% compared to the S&P 500's 17.14%, reinforcing the notion that the stock may be overvalued relative to its peers and the broader market.

Is AC Immune SA technically bullish or bearish?

As of June 4, 2025, AC Immune SA shows a mildly bearish trend with mixed signals across time frames, having outperformed the S&P 500 in the short term but significantly underperformed over the past year.

As of 4 June 2025, the technical trend for AC Immune SA has changed from bearish to mildly bearish. The current stance is mildly bearish, driven by daily moving averages indicating a bearish sentiment, while the weekly MACD and Bollinger Bands show bullish signals. However, the monthly MACD and KST are bearish, suggesting mixed signals across different time frames. The Dow Theory indicates a mildly bullish stance on both weekly and monthly charts, while the On-Balance Volume (OBV) also reflects a mildly bullish trend.<BR><BR>In terms of performance, AC Immune has outperformed the S&P 500 over the past week and month, with returns of 5.88% and 17.21% respectively, but it has significantly underperformed over longer periods, including a -30.58% return over the past year compared to the S&P 500's 17.14%.